Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 5,400 shares of its common stock under the Company's 2023 Inducement Plan.
加利福尼亞州布里斯班，2024年4月26日（GLOBE NEWSWIRE）——Tempest Therapeutics, Inc.（納斯達克股票代碼：TPST），一家處於臨床階段的生物技術公司，正在開發同類首創1 抗癌的靶向和免疫介導療法今天宣佈，公司董事會薪酬委員會授予一名員工不合格股票期權，根據公司的2023年激勵計劃，購買總共5,400股普通股。
The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary of such employee's start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
股票期權將在四年內歸屬，每份期權的25％將在該員工入職一週年之際歸屬，此後將有1/48的股票總額按月歸屬，但每個歸屬日仍需繼續僱用。
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at www.tempesttx.com.
關於《暴風雨》
Tempest Therapeutics是一家處於臨床階段的生物技術公司，正在推進多元化的小分子候選產品組合，這些候選產品包含腫瘤靶向和/或免疫介導的機制，有可能治療各種腫瘤。該公司的新項目包括針對一線癌症患者的隨機全球研究的早期研究到後期研究。Tempest 總部位於加利福尼亞州布里斯班。有關 Tempest 的更多信息可以在該公司的網站上找到 www.tempesttx.com。
Investor & Media Contacts:
投資者和媒體聯繫人：
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
西爾維亞·惠勒
惠爾豪斯生命科學顧問
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Aljanae Reynolds
惠爾豪斯生命科學顧問
areynolds@wheelhouselsa.com
1 If approved by the FDA
1 如果獲得美國食品和藥物管理局的批准
譯文內容由第三人軟體翻譯。